Finoriq

Finoriq research workspace

DEXCOM INC (DXCM) Company Overview

DEXCOM INC offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6. Review DXCM filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Company
DEXCOM INC (DXCM)
Ticker
DXCM
Market Cap
$29.3B
Latest Price
$75.88
Industry
Medical Devices

Open insider transactions

DEXCOM INC (DXCM) Current Valuation Metrics

Static valuation preview for DEXCOM INC (DXCM). Market data retrieved 2026-07-08. Filing currency USD.

MetricValueSource
P/EMarket cap divided by latest TTM net income.30.6xNet Income | TTM Q1 2026
P/SMarket cap divided by latest TTM revenue.5.91xRevenue | TTM Q1 2026
P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow.16.0xOperating Cash Flow | TTM Q1 2026
Earnings YieldLatest TTM net income divided by market cap.3.3%Net Income | TTM Q1 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.6.3%Operating Cash Flow | TTM Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.